Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v2-FR | Version v1-EN | |
---|---|---|
Language | French | English |
Date Updated | 2021-08-23 | 2021-08-23 |
Drug Identification Number | 02358336 | 02358336 |
Brand name | IMIPENEM AND CILASTATIN FOR INJECTION USP | IMIPENEM AND CILASTATIN FOR INJECTION USP |
Common or Proper name | IMIPENEM AND CILASTATIN FOR INJECTION USP | IMIPENEM AND CILASTATIN FOR INJECTION USP |
Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
Ingredients | CILASTATIN IMIPENEM | CILASTATIN IMIPENEM |
Strength(s) | 250MG 250MG | 250MG 250MG |
Dosage form(s) | POWDER FOR SOLUTION | POWDER FOR SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 10PSOIJ CA | 10PSOIJ CA |
ATC code | J01DH | J01DH |
ATC description | OTHER BETA-LACTAM ANTIBACTERIALS | OTHER BETA-LACTAM ANTIBACTERIALS |
Reason for discontinuation | Business reasons | Business reasons |
Anticipated discontinuation date | ||
Actual discontinuation date | 2021-08-20 | 2021-08-20 |
Remaining supply date | 2021-08-20 | 2021-08-20 |
Discontinuation status | Discontinued | Discontinued |
Discontinuation decision reversal | no | no |
Tier 3 Status | No | No |
Information on remaining supply | ||
Company comments | ||
Health Canada comments |